XML 78 R44.htm IDEA: XBRL DOCUMENT v3.20.4
Revenue - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Dec. 31, 2020
Feb. 28, 2019
Dec. 31, 2015
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disaggregation Of Revenue [Line Items]            
Revenue recognized $ 61,600,000     $ (69,823,000)    
Revenue from collaboration agreement       98,382,000 $ 85,071,000 $ 55,663,000
Translational Development Agreements            
Disaggregation Of Revenue [Line Items]            
Term of agreement     4 years      
Agreement termination amount receivable     $ 800,000      
Eligible payments receivable     2,300,000      
Revenue recognized excluding separately negotiated research sequencing contracts         2,300,000 9,300,000
Translational Development Agreements | Maximum            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments     $ 40,000,000.0      
MRD Development Agreements            
Disaggregation Of Revenue [Line Items]            
Milestone revenue recognized       2,500,000 2,000,000.0 10,000,000.0
Revenue recognized       3,400,000 3,700,000 $ 12,800,000
MRD Development Agreements | Maximum            
Disaggregation Of Revenue [Line Items]            
Additional milestone payment receivable 313,500,000     313,500,000    
Genentech Collaboration Agreement            
Disaggregation Of Revenue [Line Items]            
Non-refundable upfront payments received   $ 300,000,000.0   300,000,000.0    
Revenue from collaboration agreement       $ 52,800,000 $ 35,100,000  
Genentech Collaboration Agreement | Maximum            
Disaggregation Of Revenue [Line Items]            
Revenue recognition expected period       8 years    
Genentech Collaboration Agreement | Maximum | Regulatory Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 75,000,000.0     $ 75,000,000.0    
Genentech Collaboration Agreement | Maximum | Development Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 300,000,000.0     300,000,000.0    
Genentech Collaboration Agreement | Maximum | Commercial Milestones            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments 1,430,000,000.0     1,430,000,000.0    
Genentech Collaboration Agreement | Minimum            
Disaggregation Of Revenue [Line Items]            
Expected revenue through milestone payments $ 1,800,000     $ 1,800,000    
Revenue recognition expected period       7 years